跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
林 志慶
教授
醫學系內科學科
電子郵件
lincc2
vghtpe.gov
tw
h-index
h10-index
h5-index
2234
引文
27
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1143
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
377
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1998 …
2024
每年研究成果
概覽
指紋
網路
研究成果
(168)
類似的個人檔案
(6)
指紋
查看啟用 Chih-Ching Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Angiotensin Receptor Blockers
8%
Arteriovenous Fistula
46%
Arteriovenous Graft
13%
Asymmetric Dimethylarginine
13%
Chronic Kidney Disease
23%
Clinical Outcomes
10%
Confidence Interval
14%
Continuous Ambulatory Peritoneal Dialysis
11%
Continuous Erythropoietin Receptor Activator
12%
Diabetes
9%
Diabetic Kidney Disease
8%
Diabetic Nephropathy
9%
Dialysis
17%
Dialysis Access
8%
Dialysis Membrane
10%
Dialysis Patients
8%
End-stage Kidney Disease
9%
End-stage Renal Disease
11%
Epidemiology
7%
Erythropoiesis-stimulating Agents
10%
Far-infrared
9%
Far-infrared Therapy
41%
Fistula Patency
14%
Genotype
9%
Genotype Polymorphism
10%
Hazard Ratio
17%
Hematocrit
10%
Heme oxygenase-1 (HO-1)
16%
Hemodialysis
45%
Hemodialysis Patients
86%
Hemodialysis Vascular Access
14%
High Risk
9%
Hypoglycemia
8%
Maintenance Hemodialysis Patients
26%
National Cohort Study
13%
Patency
22%
Perfluorohexanoic Acid (PFHxA)
11%
Peritoneal Dialysis
34%
Peritoneal Dialysis Patients
23%
Protein-to-creatinine Ratio
8%
Proteinuria
10%
Randomized Controlled Trial
11%
Risk Factors
14%
South Asia
10%
South-East Asia
13%
Taiwan
27%
Uremic Patients
22%
Vascular Access
29%
Vascular Thrombosis
7%
Yoga
8%
Medicine and Dentistry
Acute Kidney Injury
5%
Analeptic
5%
Ankle Brachial Index
6%
Apoplexy
8%
Arteriovenous Fistula
21%
Bleeding
5%
Blood Pressure
8%
Canagliflozin
6%
Cardiovascular System
6%
Chronic Kidney Disease
24%
Clinical Trial
6%
Cohort Analysis
11%
Cohort Effect
7%
Continuous Ambulatory Peritoneal Dialysis
7%
Continuous Erythropoiesis Receptor Activator
5%
Coronavirinae
6%
Diabetes
11%
Diabetes Mellitus
11%
Diabetic Nephropathy
18%
Dialysis Catheter
6%
End Stage Renal Disease
24%
Glomerulonephritis
8%
Hazard Ratio
10%
Health Care Cost
5%
Heat Therapy
23%
Hematocrit
6%
Hemodialysis
81%
Hypoglycemia
6%
Immunosuppressive Drug
5%
Infection
5%
Kidney Function
6%
Meta-Analysis
6%
N(g),n(g) Dimethylarginine
9%
Nephrology
8%
Nephropathy
12%
Nutritional Status
5%
Patient with Diabetes
7%
Peritoneal Dialysis
41%
Peritonitis
6%
Pneumocystis Pneumonia
6%
Podocyte
6%
Prevalence
10%
Prognostic Factor
7%
Quality of Life
5%
Randomized Controlled Trial
13%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Therapeutic Modality
5%
Vascular Access
27%
Yoga
6%
Pharmacology, Toxicology and Pharmaceutical Science
6 N,n' Dimethylarginine
13%
Acrolein
6%
Acute Kidney Failure
8%
Anemia
5%
Angiotensin
5%
Angiotensin Receptor Antagonist
8%
Arteriovenous Fistula
41%
Atrial Fibrillation
6%
Brain Ischemia
5%
C Reactive Protein
7%
Canagliflozin
6%
Cardiovascular Disease
7%
Chronic Kidney Failure
19%
Clinical Trial
6%
Cohort Study
16%
Continuous Erythropoiesis Receptor Activator
9%
Coronavirinae
10%
Creatinine
10%
Diabetes Mellitus
8%
Diabetic Nephropathy
19%
Dipeptidyl Carboxypeptidase Inhibitor
7%
Dipeptidyl Peptidase IV Inhibitor
6%
Disease
9%
End Stage Renal Disease
20%
Glucose Degradation Product
5%
Heart Failure
6%
Heme Oxygenase 1
11%
Hemodialysis
100%
Hypoglycemia
8%
Infection
5%
Inflammation
13%
Kidney Disease
13%
Kidney Fibrosis
6%
N(g),n(g) Dimethylarginine
13%
Non Insulin Dependent Diabetes Mellitus
8%
Perfluoro Compound
6%
Perfluorooctanesulfonic Acid
8%
Perfluorooctanoic Acid
5%
Peritonitis
6%
Polysulfone
5%
Randomized Controlled Trial
17%
Renin
5%
Retrospective Study
5%
SARS Coronavirus
5%
Sodium Glucose Cotransporter 2 Inhibitor
6%
